JP2011526891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526891A5 JP2011526891A5 JP2011516335A JP2011516335A JP2011526891A5 JP 2011526891 A5 JP2011526891 A5 JP 2011526891A5 JP 2011516335 A JP2011516335 A JP 2011516335A JP 2011516335 A JP2011516335 A JP 2011516335A JP 2011526891 A5 JP2011526891 A5 JP 2011526891A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- fusion protein
- protein
- trail
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 24
- 108020001507 fusion proteins Proteins 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims description 5
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 5
- 108700012411 TNFSF10 Proteins 0.000 claims description 5
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims description 5
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims description 4
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 2
- 101000648505 Homo sapiens Tumor necrosis factor receptor superfamily member 12A Proteins 0.000 claims description 2
- 102000055458 human TNFRSF12A Human genes 0.000 claims description 2
- 102000044949 human TNFSF10 Human genes 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150026580 CD5 gene Proteins 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000981093 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 description 1
- 101000650817 Homo sapiens Semaphorin-4D Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101100166612 Mus musculus Cd72 gene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- -1 PDL-2 Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13353208P | 2008-06-30 | 2008-06-30 | |
| US61/133,532 | 2008-06-30 | ||
| PCT/US2009/003886 WO2010005519A1 (en) | 2008-06-30 | 2009-06-30 | Fn14/trail fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011526891A JP2011526891A (ja) | 2011-10-20 |
| JP2011526891A5 true JP2011526891A5 (https=) | 2012-08-16 |
| JP5475766B2 JP5475766B2 (ja) | 2014-04-16 |
Family
ID=41278748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516335A Active JP5475766B2 (ja) | 2008-06-30 | 2009-06-30 | Ｆｎ１４／ＴＲＡＩＬ融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8039437B2 (https=) |
| EP (2) | EP2297198B1 (https=) |
| JP (1) | JP5475766B2 (https=) |
| CN (1) | CN102137869B (https=) |
| AU (1) | AU2009269141B2 (https=) |
| CA (1) | CA2729351C (https=) |
| IL (1) | IL210175A0 (https=) |
| SG (1) | SG191698A1 (https=) |
| WO (1) | WO2010005519A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| AU2011309689B2 (en) | 2010-09-28 | 2015-01-15 | Hadasit Medical Research Services & Development Ltd. | Compositions and methods for treatment of hematological malignancies |
| PL219845B1 (pl) * | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| CN102206281B (zh) * | 2011-03-28 | 2014-04-09 | 中国人民解放军第三军医大学第一附属医院 | 融合蛋白tetph、表达载体及其构建方法 |
| WO2012145568A1 (en) | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| PL397167A1 (pl) * | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| WO2014121085A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| WO2014121099A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
| US9238034B2 (en) | 2013-07-09 | 2016-01-19 | The Translational Genomics Research Institute | FN14 antagonists and therapeutic uses thereof |
| JP2017525370A (ja) | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法 |
| AU2016227322A1 (en) * | 2015-03-03 | 2017-09-21 | Kahr Medical Ltd | Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases |
| JP6981973B2 (ja) | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11267856B2 (en) | 2017-02-27 | 2022-03-08 | Shattuck Labs, Inc. | CSF1R-CD40L chimeric proteins |
| US20190367579A1 (en) | 2017-02-27 | 2019-12-05 | Shattuck Labs, Inc. | Tigit- and light-based chimeric proteins |
| EP4249503A3 (en) | 2017-02-27 | 2023-12-20 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
| CN111819198A (zh) * | 2017-12-28 | 2020-10-23 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| US20220267409A1 (en) | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| EP2298333A3 (en) | 1999-12-20 | 2012-05-02 | Immunex Corporation | Tweak receptor |
| US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| US7378089B2 (en) | 2001-10-02 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Gene therapy for the prevention of autoimmune disease |
| MX352180B (es) * | 2002-04-09 | 2017-11-13 | Biogen Ma Inc | El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak. |
| DE60336746D1 (de) * | 2002-10-29 | 2011-05-26 | Anaphore Inc | Trimer-proteine zur trimer-zytokine |
| DE602004006871T2 (de) * | 2003-07-24 | 2008-02-07 | Amgen Inc., Thousand Oaks | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen |
| US7285522B2 (en) | 2004-08-25 | 2007-10-23 | The Clorox Company | Bleaching with improved whitening |
-
2009
- 2009-06-30 CA CA2729351A patent/CA2729351C/en active Active
- 2009-06-30 US US12/494,680 patent/US8039437B2/en active Active
- 2009-06-30 EP EP09788855.6A patent/EP2297198B1/en active Active
- 2009-06-30 JP JP2011516335A patent/JP5475766B2/ja active Active
- 2009-06-30 SG SG2013049333A patent/SG191698A1/en unknown
- 2009-06-30 EP EP12001349A patent/EP2460827A1/en not_active Ceased
- 2009-06-30 CN CN200980133865.2A patent/CN102137869B/zh active Active
- 2009-06-30 WO PCT/US2009/003886 patent/WO2010005519A1/en not_active Ceased
- 2009-06-30 AU AU2009269141A patent/AU2009269141B2/en active Active
-
2010
- 2010-12-22 IL IL210175A patent/IL210175A0/en active IP Right Grant
-
2011
- 2011-08-11 US US13/208,091 patent/US8329657B2/en active Active
-
2012
- 2012-08-15 US US13/586,479 patent/US20130065815A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526891A5 (https=) | ||
| US11357826B2 (en) | IL-10 EGFR antibody fusion protein and uses thereof | |
| EP3638700B1 (en) | Proteinaceous heterodimer and use thereof | |
| CN112584851B (zh) | 新型白介素-15(il-15)融合蛋白及其用途 | |
| RU2644243C2 (ru) | Химерные антигенные рецепторы к cd22 | |
| TWI826358B (zh) | 用於治療肌肉萎縮和骨疾病的新型雜合ａｃｔｒｉｉｂ配體陷阱蛋白及其用途與生產方法 | |
| US20200087377A1 (en) | Multifunctional Fusion Protein and Applications Thereof | |
| KR102128966B1 (ko) | 종양 투과성 펩타이드와 항-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물 | |
| JP2020506727A5 (https=) | ||
| JP2010539236A5 (https=) | ||
| CN108473575A (zh) | 抗-bcma多肽和蛋白质 | |
| JP2009541492A5 (https=) | ||
| MX2010002053A (es) | Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. | |
| EP2912061A1 (en) | M971 chimeric antigen receptors | |
| EP3097123A1 (en) | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors | |
| KR20180030898A (ko) | Gdf15의 활성 감소용 제제 | |
| WO2018213612A1 (en) | Anti-mesothelin polypeptides and proteins | |
| CN100549175C (zh) | 一种具有抑癌作用的重组蛋白及其编码基因与应用 | |
| US20230391863A1 (en) | Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof | |
| WO2019204402A1 (en) | Compositions and methods for treatment of cancer | |
| JP2025531805A (ja) | 新規のｐｄ１標的化ｉｌ－１５免疫サイトカインおよびｖｉｔｏｋｉｎｅ融合物 | |
| CA3196077A1 (en) | Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof | |
| CN116635059A (zh) | 激活蛋白和肿瘤坏死因子-α的双功能拮抗剂及其用途 | |
| CN120390653A (zh) | Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法 | |
| CN114929255A (zh) | DKK3b的肽模拟物及使用方法 |